Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram

Overview of attention for article published in Frontiers in immunology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,678 followers.

RT @AngeloDipa_: Which patient may benefit from inclusion in an early-phase trial with next-generation #immunotherapies⁉️🩺 📣 Find out our…

20 Jan 2024

Reply Repost Favourite

Which patient may benefit from inclusion in an early-phase trial with next-generation #immunotherapies⁉️🩺 📣 Find out our experience with interesting observations and a handy prognostic #nomogram for clinical practice ✅ https://t.co/o45vD8jJFS @OncoAler

20 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.